Feature | January 29, 2013

Transparent Pricing Does Not Curb Doctors’ Use of High-Cost Hospital Imaging Tests

MRI, CT Systems Imaging Transparent Pricing Study

January 29, 2013 — In a study designed to see if doctors who are told the exact price of expensive medical tests like magnetic resonance imaging (MRI) in advance would order fewer of them, Johns Hopkins researchers got their answer: No.

In a report published online in the Journal of the American College of Radiology, the researchers found that revealing the costs of MRIs and other imaging tests up front had no impact on the number of tests doctors ordered for their hospitalized patients.

“Cost alone does not seem to be the determining factor in deciding to go ahead with an expensive radiographic test,” says the study’s senior author, Daniel J. Brotman, M.D., an associate professor of medicine at the Johns Hopkins University School of Medicine and director of the hospitalist program at The Johns Hopkins Hospital. “There is definitely an over-ordering of tests in this country, and we can make better decisions about whether our patients truly need each test we order for them. But when it comes to big-ticket tests like MRI, it appears the doctors have already decided they need to know the information, regardless of the cost of the test.”

Studies in the past suggest that much of the expense of laboratory tests, medical imaging and prescription drugs is unknown or hidden from providers and patients at the time of ordering, leaving financial considerations largely out of the health care decision-making process and likely driving up costs, Brotman notes.

Other studies have shown that doctors ordered fewer laboratory tests in some cases when they were given the price up front. But Brotman says imaging tests appear to be “a different animal.”

There are built-in disincentives to ordering many major tests if they are not necessary, such as the potential danger of radiation used in some, Brotman says. In addition to making physicians more sensitive to the costliness of unnecessary testing, Brotman says they need to learn how to explain to patients why they may not need them.

For the study, Brotman and his colleagues identified the 10 imaging tests most frequently ordered for patients at The Johns Hopkins Hospital. Dividing the tests into two groups, they made sure prices were attached to one group over a six-month period, from November 2009 to May 2010. Brotman and his colleagues left out the pricing information for the other group over the same time period. Prices are not typically shared with physicians or patients in most medical settings.

When the researchers compared the ordering rates to the rates from a six-month period a year earlier, when no costs were displayed at all, they found no significant difference in ordering patterns.

Brotman says he might have been concerned if there was a large decrease in ordering expensive tests, as there are many instances when the expensive test is justified. For example, when a patient appears to have had a sub-acute stroke, an MRI is often justified “regardless of cost,” he says. “When a key diagnosis is needed in imaging, there are limited options for comparison shopping.”

That is not to say there are not times when physicians need to look more closely at whether too many imaging tests are being ordered, Brotman says. For example, patients in a hospital intensive care unit who are on a ventilator and unable to tell doctors how they are feeling may not need a daily chest X-ray to scan for potential problems. Brotman says there is evidence that outcomes are not compromised if X-rays are ordered only when the patient’s condition appears to be worsening. MRIs are also ordered too frequently for lower back pain, he says.

“For too long, there has not been enough attention paid to the bottom line in health care,” Brotman says. This is not about rationing care to hold down costs, he says, but about choosing tests a little more wisely. “There are financial consequences for the choices we make, and for too long we haven’t considered them,” he says.

Even though price transparency did not influence the way physicians ordered imaging tests in his study, Brotman says financial considerations may play a role in other circumstances if tied to clinical evidence.

For example, he says, when clinical programs began to compare the amount of blood products used by surgeons, those who were using far more than their peers (and with similar patient outcomes) took note and reduced their reliance on transfusions, which are not only costly but also carry risks.

If you show a provider that he or she is ordering four times as many computed tomography (CT) scans as a colleague whose patients have similar outcomes, it could change the decision-making calculus for the better, he says.

“Cost transparency must be part of the solution to solving fiscal challenges in medicine,” Brotman says. “Providers have no idea how much they’re spending. Patients don’t know either. Having everyone understand more of the economics of health care is a great place to start cutting costs in medicine.”

The study was supported, in part, by the Research and Education Foundation of the Radiological Society of North America, the Walter and Mary Ciceric Research Award and the Johns Hopkins Hospitalist Scholars Program.

Other Johns Hopkins researchers involved in the study include Daniel J. Durand, M.D.; Leonard S. Feldman, M.D.; and Jonathan S. Lewin, M.D.

For more information: www.hopkinsmedicine.org/gim/faculty/brotman.html

Related Content

MR angiography, MRA, Bayer, Gadavist, gadobutrol injection, FDA approval, supra-aortic arteries
Technology | Contrast Media| April 29, 2016
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use...
coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT
News | Computed Tomography (CT)| April 26, 2016
The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA)...
Toshiba, Aquilion Lightning CT, 50 kW generator, FDA clearance
News | Computed Tomography (CT)| April 20, 2016
April 19, 2016 — Toshiba America Medical Systems Inc.’s Aquilion Lightning...
FFR-CT, heartflow
Feature | CT Angiography (CTA)| April 15, 2016 | Jeff Zagoudis
Fractional flow reserve-computed tomography (FFR-CT) is still in the early stages of clinical implementation in the U
TAVR runoff image

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve repl
computed tomography, CT scans, electronic medical devices, interference, FDA
News | Computed Tomography (CT)| April 13, 2016
The U.S. Food and Drug Administration (FDA) has received a small number of reports of adverse events that are believed...
Sponsored Content | Videos | CT Angiography (CTA)| April 12, 2016
A discussion on the adoption rate of FFR-CT with Dr. Campbell Rogers, chief medical officer of HeartFlow.
News | Advanced Visualization| April 07, 2016
April 7, 2016 — Circle Cardiovascular Inc.
FFR-CT, HeartFlow, PLATFORM trial, one-year results, ACC 2016
News | CT Angiography (CTA)| April 05, 2016
Novel technology developed by HeartFlow Inc. significantly reduces the need for invasive procedures to diagnose...
Toshiba, ACC 2016, American College of Cardiology, CT, MR, ultrasound, angiography, interventional radiology

Infinix 4-D CT image courtesy of Toshiba America Medical Systems.

News | Cardiac Imaging| March 30, 2016
Toshiba America Medical Systems Inc. announced it would demonstrate the following diagnostic imaging technologies at...
Overlay Init